A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).

Akitaka Makiyama,Kosuke Sagara,Junji Kawada,Tomomi Kashiwada,Ayumu Hosokawa,Yoshiki Horie,Hironaga Satake,Yoshiyuki Yamamoto,Hiroaki Tanioka,Katsunori Shinozaki,Kazuhiro Nishikawa,Keita Uchino,Yasutaka Sukawa,Takeharu Yamanaka,Kentaro Yamazaki,Shuichi Hironaka,Narikazu Boku,Ichinosuke Hyodo,Taito Esaki,Kei Muro

A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).

2018

4011Background: Trastuzumab (Tmab) is a key drug for HER2-positive breast and gastric or gastro-esophageal junction (G/GEJ) cancer. While continuous use of Tmab beyond progression (TBP) showed a be...

Keywords:

Refractory
Oncology
Cancer
Phases of clinical research
Trastuzumab
Gastro-
Paclitaxel/trastuzumab
Pathology
Internal medicine
Medicine
gastro esophageal junction
Drug
in patient
weekly paclitaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations